На этой странице перечислены больницы направления «Ортопедия» (включая Hand Transplant) в Хайдарабад, Индия, включая KIMS Hospitals, Secunderabad, Yashoda Hospitals, Secunderabad, Apollo Hospital DRDO, Apollo Hospitals, Jubilee Hills.
Спросите нас о «Hand Transplant» в Хайдарабад, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 4 аккредитованных больниц (Ортопедия) в Хайдарабад, Индия
Рекомендуем🇮🇳 KIMS Hospitals, Secunderabad
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 743 отзывов).
🇮🇳 Yashoda Hospitals, Secunderabad
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 518 отзывов).
🇮🇳 Apollo Hospital DRDO
Больница занимает 3-е место в этом списке по указанному рейтингу (4.5/5, 82 отзывов).
🇮🇳 Apollo Hospitals, Jubilee Hills
Больница занимает 4-е место в этом списке по указанному рейтингу (4.1/5, 44 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Ортопедия» указано среди её специализаций и она находится в Хайдарабад, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «hand transplant» в Хайдарабад, Индия?
Выбор подходящей больницы для «hand transplant» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Ортопедия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Hand Transplant»
Hand transplant surgery is a complex composite tissue allotransplantation (CTA) procedure that restores upper-limb function in patients with traumatic or congenital hand loss, with leading international centers reporting functional success rates of 70–85% at five years post-transplant. GAF Healthcare connects international patients with elite, high-volume transplant teams in India and the UAE who are experienced in microsurgical nerve-vessel coaptation, immunosuppression protocols, and long-term rehabilitation — disciplines that collectively determine whether a transplanted hand achieves meaningful motor and sensory recovery. Patients choose GAF Healthcare for end-to-end case coordination, significantly lower costs compared to Western centers, and access to JCI- and NABH/DHA-accredited hospitals where hand transplant programs operate under structured multidisciplinary protocols. Hospital Stay: 21–35 days (acute inpatient phase, inclusive of transplant surgery and immediate post-operative immunosuppression stabilization) • Total Stay in Country (Fit-to-Fly): 10–16 weeks (patients must achieve stable immunosuppression trough levels, wound integrity, and early physiotherapy milestones before international air travel is medically cleared) • Success Rate: 70–85% functional graft survival at 5 years (defined as protective sensation, basic grip, and absence of rejection-related graft loss)
Clinical Overview
Hand transplant surgery — formally classified as vascularized composite allotransplantation (VCA) — involves the surgical reattachment of a donor hand (and in bilateral cases, both hands) from a brain-dead or cardiac-death donor to a recipient whose own hand has been lost through trauma, malignancy resection, or severe infection such as necrotizing fasciitis or meningococcal sepsis. Unlike solid organ transplantation, a hand allograft is a composite unit comprising skin, subcutaneous tissue, tendons, bone, cartilage, nerves, lymphatics, and multiple distinct vascular pedicles, making it immunologically more complex and rejection monitoring substantially more demanding. The procedure requires ABO blood group compatibility, HLA tissue typing, and a negative cross-match; donor-recipient limb anthropometry (bone diameter, vessel caliber, skin color) is carefully matched to optimize both functional and aesthetic outcomes. The physiological impact of hand loss extends far beyond mechanical disability. Patients suffer measurable degradation of proprioceptive feedback, cortical hand-area remapping in the sensorimotor cortex, and profound psychosocial sequelae including depression, PTSD, and occupational inability. Body image disruption is particularly severe in bilateral amputees. Hand transplantation addresses these deficits through biological restoration: regenerating peripheral nerve fibers grow at approximately 1 mm per day along donor Schwann cell scaffolds, eventually producing protective sensation (usually by 6–12 months) and discriminative touch (12–36 months), with cortical remapping reverting toward normal as reinnervation progresses — a phenomenon documented on functional MRI studies in long-term recipients. The current standard of care follows protocols refined through the International Registry on Hand and Composite Tissue Transplantation (IRHCTT) and landmark programs at institutions such as the University of Pittsburgh Medical Center, Innsbruck Medical University, and Louisville Jewish Hospital. Immunosuppression is triple-drug therapy comprising a calcineurin inhibitor (tacrolimus, target trough 10–15 ng/mL in the first year), an antiproliferative agent (mycophenolate mofetil 2–3 g/day), and a corticosteroid (tapered prednisone). Induction therapy with basiliximab or anti-thymocyte globulin (ATG) is standard. Rejection surveillance relies on serial clinical inspection for skin erythema and edema, Banff 2007 VCA rejection grading on punch biopsy specimens, and emerging biomarkers such as donor-derived cell-free DNA (dd-cfDNA). Indian and UAE centers partnered with GAF Healthcare adhere to these internationally validated protocols.
Who is a Candidate?
• IDEAL CANDIDATES: • Unilateral or bilateral hand amputees resulting from traumatic avulsion, blast injury, crush injury, burns, or malignancy resection, where prosthetic rehabilitation has failed to restore functional satisfaction • Patients aged 18–55 years (younger recipients show superior nerve regeneration rates; age >60 is a relative contraindication due to slower axonal regrowth and higher immunosuppression-related comorbidity risk) • Amputation level at or distal to the mid-forearm (transcarpal, wrist disarticulation, or below-elbow stumps with preserved forearm musculature provide the best functional substrates) • Patients who have demonstrated psychological stability, realistic expectations, high motivation for intensive rehabilitation (minimum 2 years), and compliance with lifelong immunosuppression • BMI ≤ 32 kg/m² (obesity increases surgical complexity and wound complication rates) • Non-smokers or confirmed ex-smokers (≥ 6 months cessation); nicotine causes microvascular vasoconstriction and significantly elevates thrombosis risk in anastomosed vessels • REQUIRED PRE-OPERATIVE DIAGNOSTICS: • Complete HLA typing (Class I: HLA-A, B, C; Class II: HLA-DR, DQ, DP) and ABO/Rh blood group confirmation • Lymphocyte cross-match (complement-dependent cytotoxicity and flow cytometry) — must be negative • Panel Reactive Antibody (PRA) screen to quantify pre-formed donor-specific antibodies (DSA); high PRA (>20%) may require desensitization • Contrast-enhanced CT angiography (CECT) of the stump/residual limb vasculature to assess radial/ulnar artery patency and caliber • Nerve conduction studies (NCS) and electromyography (EMG) of residual forearm musculature to confirm viable motor unit recruitment • Full cardiac evaluation: ECG, transthoracic echocardiography (ECHO), and stress test if age >40 or cardiac history, to assess fitness for prolonged general anesthesia (8–14 hours) • Renal function panel (eGFR, serum creatinine), liver function tests, HbA1c — baseline organ reserve essential before tacrolimus initiation • Infectious disease screening: HIV, Hepatitis B (HBsAg, anti-HBc), Hepatitis C (anti-HCV + PCR), CMV IgG/IgM, EBV, TB (Quantiferon-TB Gold or Mantoux) • Psychiatric evaluation using validated tools (MMPI-2, SCL-90) and formal psychosocial assessment by a transplant psychologist • Bone density scan (DEXA) if long-term corticosteroid use is anticipated • ABSOLUTE CONTRAINDICATIONS: • Active malignancy or remission < 5 years for most solid tumors • Severe cardiovascular disease with EF < 35% or unrevascularizable coronary artery disease • Uncontrolled diabetes mellitus (HbA1c > 9%) or severe diabetic vasculopathy • Active systemic infection, sepsis, or untreated TB • Significant psychiatric illness that precludes informed consent or reliable medication adherence (active schizophrenia, severe untreated bipolar disorder) • Severe coagulopathy or bleeding disorder incompatible with anticoagulation management • Known allergy or hypersensitivity to required immunosuppressants • Patients unwilling to accept lifelong immunosuppression and its attendant risks
Treatment Options & Approaches
MICROSURGICAL TECHNIQUE — THE CORE PROCEDURE: Hand transplantation is performed under general anesthesia with continuous arterial line and central venous monitoring. The surgical team (typically 8–14 surgeons and technicians working in relay) proceeds through sequential anatomical layers: 1. Skeletal fixation: Donor and recipient bone ends are prepared and fixed using low-profile locking compression plates (LCP) or intramedullary fixation at the radius/ulna or metacarpal level. Rigid bony union is the foundation for subsequent tissue repair and early rehabilitation. 2. Tendon repair: Flexor digitorum profundus (FDP), flexor digitorum superficialis (FDS), and extensor tendons are repaired using modified Kessler or Adelaide four-strand core sutures with peripheral epitendinous running sutures, optimized for gliding strength. 3. Arterial anastomosis: Radial and ulnar arteries are repaired under operating microscope (×10–×16 magnification) using 8-0 or 9-0 monofilament nylon interrupted sutures, with pharmacological vasodilation (papaverine, lidocaine irrigation) and systemic heparinization (ACT-guided) to prevent thrombosis. Doppler ultrasound confirms pulsatile flow immediately post-anastomosis. 4. Venous anastomosis: A minimum of two dorsal venae comitantes per artery are repaired to ensure adequate drainage and prevent venous congestion, the leading cause of early graft loss. 5. Nerve coaptation: Median, ulnar, and radial nerves are repaired under high magnification using epineurial sutures (9-0 or 10-0 nylon) or, where significant tension exists, donor nerve conduits or acellular nerve allografts (e.g., AxoGen Avance) to bridge gaps without tension. Fascicular or group fascicular repair is used where nerve anatomy permits. 6. Skin closure: Meticulous layered skin closure with preservation of superficial venous and lymphatic channels. Skin grafting may be required at the stump-donor interface. BILATERAL HAND TRANSPLANTATION: For bilateral amputees, the same sequence is performed simultaneously by two separate surgical teams on each limb, extending total operative time to 14–18 hours. Bilateral recipients gain greater independence benefit but face doubled immunological exposure and higher surgical risk. INTRAOPERATIVE MONITORING TECHNOLOGIES: • Indocyanine green (ICG) fluorescence angiography to confirm perfusion patterns in the transplanted hand • Implantable Doppler probes (Cook-Swartz) placed on anastomosed vessels for continuous post-operative vascular monitoring in the ICU • Near-infrared spectroscopy (NIRS) for real-time tissue oxygenation monitoring DONOR LIMB PRESERVATION: Cold ischemia time should be minimized to < 6 hours (ideally < 4 hours). Preservation solutions (University of Wisconsin solution or Custodiol HTK) are used for flush and static cold storage. Machine perfusion protocols for limb allografts are under investigation at leading centers. IMMUNOSUPPRESSION PROTOCOLS: Triple immunosuppression is initiated at the time of reperfusion: • Tacrolimus (FK506): target trough 10–15 ng/mL (Year 1), tapering to 8–12 ng/mL thereafter; monitored twice weekly initially, then monthly • Mycophenolate Mofetil (MMF): 1–1.5 g twice daily, adjusted for GI tolerance and WBC count • Prednisolone: 1 mg/kg/day tapered to 5–10 mg/day maintenance by Month 3 • Induction: Basiliximab (20 mg on Day 0 and Day 4) OR rabbit ATG (1.5 mg/kg/day for 5 days) for high-risk recipients ACUTE REJECTION MANAGEMENT: Banff Grade I/II acute cellular rejection (the most common, characterized by perivascular lymphocytic infiltration on skin punch biopsy) is managed with pulse IV methylprednisolone (500 mg × 3 days) and tacrolimus dose escalation. Steroid-refractory rejection may require ATG or plasmapheresis for antibody-mediated rejection (AMR). EMERGING APPROACHES: • Tolerance induction protocols: Bone marrow co-transplantation from the same donor (combined BMT + VCA) to induce operational tolerance and reduce or eliminate maintenance immunosuppression — currently in clinical trial phases at select centers • Regenerative nerve enhancement: Topical or systemic neurotrophin-3 (NT-3) and GDNF delivery to accelerate axonal regeneration • 3D-printed surgical planning models derived from CT angiography data for preoperative rehearsal of complex stump geometries
Восстановление
PHASE 1 — REMOTE EVALUATION (Weeks 1–4, before travel): The patient submits medical records to GAF Healthcare, which are reviewed by the transplant surgical team. A virtual consultation is scheduled. If the patient is deemed a potential candidate, a formal work-up list is issued. Most baseline investigations (HLA typing, cardiac ECHO, NCS/EMG, infectious disease serology) can be completed at the patient's home country and uploaded securely. GAF Healthcare coordinates translation of all reports. PHASE 2 — TRANSPLANT REGISTRATION & WAIT-LISTING (Variable, 1–18 months): The patient travels to India or UAE for in-person assessment, psychiatric evaluation, cross-match testing, and formal listing on the hospital's deceased-donor VCA waitlist. Because hand transplant donors are rare (requiring a brain-dead donor with compatible limb anthropometry, blood group, and HLA), waiting periods are highly variable. During this phase, patients may return home and are placed on 24-hour call-back notice when a suitable donor is identified. PHASE 3 — EMERGENCY TRAVEL ON DONOR IDENTIFICATION (48–72 hours): When a compatible donor hand becomes available, GAF Healthcare activates the patient's rapid-travel protocol — emergency visa facilitation, flight booking, and airport transfer — with a target arrival at the transplant center within 4–6 hours of notification when possible. PHASE 4 — PRE-OPERATIVE PREPARATION (24–48 hours before surgery): • Final cross-match performed with donor lymphocytes • Cardiac and anesthetic clearance • Induction immunosuppression initiated (basiliximab or ATG) • Bowel preparation, antibiotic prophylaxis (broad-spectrum, including anti-fungal coverage) • Informed consent finalized • Psychological support session PHASE 5 — SURGICAL PROCEDURE (Day 0, 8–18 hours operative time): Surgery performed under general endotracheal anesthesia. Sequential repair of bone, tendons, arteries, veins, and nerves as detailed in Treatment Options. The patient is transferred to the Transplant ICU on completion. PHASE 6 — ICU MONITORING (Days 1–5): • Hourly clinical assessment of hand perfusion (color, capillary refill, turgor, temperature, Doppler signal) • Continuous implantable Doppler or NIRS monitoring • Tacrolimus and MMF dose adjustment based on twice-daily trough levels • IV anticoagulation (heparin infusion) titrated to PTT 50–70 seconds for first 72 hours, then transitioned to aspirin + low-molecular-weight heparin • Vigilance for vascular thrombosis (requires emergency return to OR within 4–6 hours of detection for thrombectomy and reanastomosis) • Pain management: multimodal (regional nerve blocks, IV opioids, IV paracetamol), transitioning to oral analgesia PHASE 7 — WARD PHASE & EARLY REHABILITATION (Days 6–21): • Oral immunosuppression consolidated; weekly tacrolimus trough monitoring • First skin punch biopsy at Day 7–10 for Banff grading baseline • Wound care and gentle dressing changes • Hand therapy begins Day 5–7: passive range-of-motion exercises by certified hand therapist, edema management with elevation and compression • Occupational therapy assessment: functional goal setting • Nutritional support: dietitian-guided high-protein diet to support healing • Patient and caregiver immunosuppression education sessions PHASE 8 — EXTENDED INPATIENT/OUTPATIENT REHABILITATION (Weeks 4–12, in-country): • Daily hand therapy: progression from passive to active-assisted to active range-of-motion • Sensory re-education commences as protective sensation returns (usually Month 2–4) • Muscle re-education using electromyographic (EMG) biofeedback • Tacrolimus trough monitoring transitions to biweekly, then monthly • Serial skin biopsies at Months 1, 3, and 6 • GAF Healthcare arranges outpatient physiotherapy at accredited facilities and hotel/apartment accommodation for the patient and accompanying caregiver PHASE 9 — FIT-TO-FLY CLEARANCE & DEPARTURE (Weeks 10–16): The transplant physician issues fit-to-fly clearance when all of the following are met: • Stable tacrolimus trough levels within target range for ≥ 4 consecutive weeks • No active rejection episode in the preceding 3 weeks • Surgical wounds fully epithelialized • No active infection • Patient and home-country treating physician have received full immunosuppression protocol, biopsy schedule, and emergency contact plan • GAF Healthcare arranges onward medical record transfer and a telemedicine follow-up schedule PHASE 10 — LONG-TERM RECOVERY (Months 4–36, at home with remote monitoring): • Nerve regeneration continues; protective sensation typically by Month 6–12, discriminative touch and intrinsic muscle activation by Month 18–36 • Annual in-person review at the transplant center (GAF Healthcare facilitates return travel coordination) • Lifelong tacrolimus, MMF, and low-dose prednisolone — non-negotiable; graft loss rate rises sharply with non-adherence • Ongoing physiotherapy and occupational therapy at home center • Cortical remapping monitored via fMRI in select research-affiliated programs
Возможные риски
Hand transplantation carries a distinct and substantial risk profile that patients must evaluate with full transparency before proceeding. The most critical early complication is vascular thrombosis of anastomosed arteries or veins, occurring in approximately 5–10% of cases and requiring emergency re-exploration within 4–6 hours; failure to salvage a thrombosed graft necessitates replantation or, ultimately, graft amputation. Primary non-function — failure of the graft to achieve meaningful reinnervation — occurs in a small but real proportion of cases, particularly in older recipients or those with long ischemia times. Acute cellular rejection affects up to 85% of recipients within the first year (most episodes are Banff Grade I–II and fully reversible with pulse steroids), but severe or recurrent rejection can lead to chronic rejection, characterized by progressive fibrosis, vasculopathy, and irreversible graft deterioration — the leading cause of late graft loss. Lifelong calcineurin inhibitor (tacrolimus) use carries its own serious consequences: nephrotoxicity leading to chronic kidney disease (CKD Stage 3+ in up to 30% of long-term VCA recipients), new-onset diabetes after transplant (NODAT), hypertension, hyperlipidemia, and increased susceptibility to bacterial, viral (CMV, EBV, BK virus), and fungal infections. Long-term immunosuppression also confers a 2–4 fold elevated risk of de novo malignancy — particularly non-melanoma skin cancer and post-transplant lymphoproliferative disorder (PTLD). Patients who develop severe immunosuppression-related complications or chronic rejection may ultimately require elective graft amputation — a psychologically devastating outcome. Additionally, nerve regeneration is incomplete and unpredictable; some patients achieve only protective sensation without fine discriminative touch or intrinsic muscle function, meaning the functional outcome may fall short of pre-operative expectations despite a technically successful vascular graft. Psychiatric sequelae — including body-image adjustment disorder, depression, and in rare cases graft rejection syndrome — affect a subset of recipients. Finally, the burden of adherence to complex medication schedules, frequent laboratory monitoring, and regular follow-up biopsies is lifelong and must be factored into the patient's psychosocial capacity. GAF Healthcare ensures all patients undergo rigorous pre-operative psychological assessment and receives structured support through transplant nurse coordinators and telemedicine access to the transplant team.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated medical tourism support infrastructure designed so that patients and their accompanying caregivers can focus entirely on the clinical process. INDIA LOGISTICS: • e-Medical Visa (eMV) facilitation: GAF Healthcare prepares and submits the e-Medical Visa application on the patient's behalf, including the mandatory hospital invitation letter from the accredited transplant center. The eMV is issued within 3–5 business days for most nationalities and permits a stay of up to 60 days, extendable twice (maximum 180 days) — critical given the 10–16 week minimum in-country period. Accompanying attendants receive the e-Medical Attendant Visa (eMAV), limited to two attendants per patient. • Airport transfers: Dedicated air-conditioned medical transport from the airport to the hospital on arrival, with a GAF Healthcare patient liaison officer present at the arrival gate. • Accommodation: GAF Healthcare arranges fully serviced apartments or hospital-affiliated guesthouses within 2 km of the transplant center for the patient's caregiver(s) during the inpatient phase, and for the patient during the outpatient rehabilitation period. Weekly housekeeping, laundry, and meal delivery services are coordinated. • Language support: Dedicated medical interpreter available for Arabic, Russian, French, Swahili, and other languages at all surgical consultations, consent meetings, physiotherapy sessions, and discharge briefings. • Hospital accreditation: GAF Healthcare exclusively partners with NABH-accredited and JCI-accredited hospitals for hand transplant procedures, ensuring compliance with international patient safety standards. UAE (DUBAI / ABU DHABI) LOGISTICS: • Visa access: Citizens of over 120 countries enter the UAE visa-free for 30–90 days. For nationalities requiring prior authorization, GAF Healthcare coordinates UAE tourist or medical visa applications. Visa extensions are processed through the General Directorate of Residency and Foreigners Affairs (GDRFA), which GAF Healthcare manages on the patient's behalf for extended rehabilitation stays. • Airport transfers: VIP meet-and-assist service at Dubai International (DXB) or Abu Dhabi International (AUH) airports, with luxury medical transfer vehicles. • Accommodation: GAF Healthcare partners with serviced hotel apartments and executive recovery suites near JCI- and DHA-licensed transplant centers in Dubai Healthcare City (DHCC) and Abu Dhabi's Cleveland Clinic Abu Dhabi precinct. Caregiver accommodation is arranged in the same building where possible. • Language support: Arabic-speaking patient coordinators are on-staff in the UAE office; English, Hindi, Urdu, and other language interpreters are available on-call. • Insurance coordination: GAF Healthcare liaises with international health insurers and government health authorities (for patients covered under national medical referral schemes from Gulf Cooperation Council countries, East Africa, or Central Asia) to provide cost-authorization documentation. CROSS-DESTINATION SUPPORT: • 24/7 emergency helpline staffed by a registered nurse coordinator • Telemedicine access to the transplant surgeon for 90 days post-departure • Comprehensive discharge package: immunosuppression prescription translation, laboratory monitoring schedule, emergency rejection recognition card, and referring physician briefing document • Flight re-booking assistance if fit-to-fly clearance is delayed for medical reasons
Частые вопросы о процедуре «Hand Transplant»
What is the cost of Hand Transplant Surgery in India compared to the UAE?
How long do I need to stay in the country before I am fit to fly home after a hand transplant?
What is the success rate of Hand Transplant Surgery?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «hand transplant» в Хайдарабад, Индия
Найдите лучшие больницы для «hand transplant» в Хайдарабад, Индия
На этой странице представлено 4 больниц в Хайдарабад, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Hand Transplant» в Хайдарабад, Индия
Сколько больниц направления «Ортопедия» представлено в Хайдарабад, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Хайдарабад, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Hand Transplant» в Хайдарабад, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.